Testosterone Enanthate East Asian Documented Efficacy Gaps

Why Testosterone Metabolism Differs by Ancestry

Testosterone Enanthate is not metabolized the same way in every patient. The ester is cleaved by serum and tissue esterases to release free testosterone, which then follows pathways governed by UDP-glucuronosyltransferases (UGTs) and cytochrome P450 aromatase. Both enzyme families carry population-stratified genetic variants that are far more common in East Asian men than in men of European descent.

UGT2B17 Deletion: The Single Largest Driver

The UGT2B17 gene encodes the primary enzyme responsible for glucuronidation of testosterone to testosterone glucuronide (TG) before urinary excretion [1]. A copy-number variant (CNV) that deletes both copies of UGT2B17 is present in roughly 70 to 80% of East Asian men and in fewer than 10% of European men [2]. Men who carry the deletion glucuronidate testosterone far more slowly. The net effect is that, at a fixed TE dose, East Asian men with the deletion clear free testosterone more slowly and sustain higher serum concentrations for longer. This is not a subtle difference. A 2007 AAPS Journal pharmacogenomic study found urinary testosterone-glucuronide excretion was reduced by greater than 90% in homozygous UGT2B17 deletion carriers compared with wild-type individuals [3].

CYP19A1 Aromatase Polymorphisms

CYP19A1 encodes aromatase, the enzyme that converts testosterone to estradiol. The rs700518 single-nucleotide polymorphism (SNP) in CYP19A1 reaches higher minor-allele frequency in East Asian populations than in European ones [4]. Men carrying the higher-activity variant aromatize testosterone faster, producing more estradiol per unit of circulating testosterone. Clinically this may translate to a lower testosterone-to-estradiol ratio at identical serum testosterone concentrations, which can blunt some androgenic end-organ effects and increase gynecomastia risk [5].

SHBG and the Free-Testosterone Fraction

Sex-hormone-binding globulin (SHBG) binds testosterone with high affinity, making it biologically inactive. Studies in Asian populations have consistently found SHBG concentrations 10 to 15% lower than age-matched European controls [6]. Lower SHBG means a higher proportion of total testosterone is free and bioavailable. When combined with slower glucuronidation from UGT2B17 deletion, an East Asian man receiving 200 mg TE every two weeks may reach free-testosterone peaks that exceed the therapeutic target range while total testosterone still appears within the labeled range.

Pharmacokinetics of Testosterone Enanthate in East Asian Men

Volume of Distribution and BMI

Testosterone is highly lipophilic. Volume of distribution (Vd) scales with body fat mass. East Asian men carry a lower average BMI (roughly 23 vs. 27 in North American men of European descent) at equivalent metabolic risk [7]. A smaller Vd concentrates a fixed dose into a smaller compartment, sharpening the Cmax peak and steepening the early AUC. This pharmacokinetic reality means the standard 200 mg IM every 2-week dose derived predominantly from European-ancestry clinical trials may produce supratherapeutic peaks in leaner East Asian men before trough concentrations normalize.

Half-Life Considerations

The nominal half-life of Testosterone Enanthate is approximately 4.5 days after IM injection, based on esterase cleavage and subsequent free-testosterone disposition [8]. Esterase activity itself is not strongly ethnicity-stratified, so the primary half-life difference in East Asian men comes from downstream clearance (UGT2B17) rather than ester hydrolysis. The practical consequence: the terminal elimination phase is prolonged in UGT2B17 deletion carriers, extending supra-normal free-testosterone exposure into the second week of a two-week injection cycle.

Serum Testosterone Trajectories: A Simulation Gap

Most pharmacokinetic models underpinning FDA-labeled dosing for TE were built on predominantly White or unspecified-ethnicity cohorts [9]. A 2002 population PK study in JCEM enrolled men of "mixed ethnicity" but did not report ancestry-stratified parameters [10]. The absence of East Asian-specific PK parameters in labeling creates a dosing framework that is not validated for this population. Clinicians relying on nomograms built from European-ancestry data may systematically underdose or overdose East Asian patients depending on which pharmacogenomic variants are present.

Clinical Trial Evidence: What Ethnicity-Stratified Data Exist

The T-Trials (NEJM 2016)

The Testosterone Trials (T-Trials) enrolled 790 men aged 65 years or older with total testosterone below 275 ng/dL and at least one qualifying symptom [11]. Participants received testosterone gel (not TE injectable) titrated to a target of 500 ng/dL, but the T-Trials remain the largest well-characterized modern TRT dataset. The trial reported outcomes including sexual function, bone density, and anemia, with statistically significant improvements in sexual function (sexual activity increased from 1.74 to 2.75 episodes per month, P<0.001) and bone density (volumetric density +7.5% at 12 months) [11]. The published data do not break down results by East Asian ancestry. The cohort was drawn from U.S. Academic centers with predominantly White enrollment, limiting direct generalizability to East Asian men.

Asian-Specific Hypogonadism Trials

A 2012 randomized trial published in the Asian Journal of Andrology enrolled 120 Chinese men with late-onset hypogonadism and assessed TE 250 mg every 3 weeks versus placebo [12]. Mean total testosterone rose from 8.1 nmol/L to 19.3 nmol/L at 12 weeks in the TE arm. The trial noted that 24% of treated men had at least one total-testosterone measurement above 30 nmol/L (roughly 865 ng/dL), which is above the Endocrine Society's upper therapeutic target, suggesting standard European-derived dosing produces supratherapeutic levels in a sizable minority of Chinese patients [12]. Hematocrit elevations above 54% occurred in 18% of the TE group versus 3% placebo (P<0.01), a polycythemia signal that may reflect the higher free-testosterone exposure driven by UGT2B17 deletion.

PharmGKB and Population Genomic Evidence

PharmGKB classifies UGT2B17 CNV as having "moderate" pharmacogenomic evidence for testosterone and androgen disposition [13]. The database notes specifically that the deletion allele is enriched in East Asian populations and that this variant alters urinary androgen excretion profiles significantly enough to affect doping control interpretation. While the PharmGKB annotation is not a clinical dosing guideline, the mechanistic evidence is well-established [13]. A 2009 Human Molecular Genetics study demonstrated that UGT2B17 deletion status accounted for 28% of the variance in urinary testosterone-glucuronide excretion across ancestry groups (N=981, P<0.0001) [14].

Endocrine Society Guidelines and Their Limitations for East Asian Men

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism recommends maintaining serum total testosterone in the mid-normal range for healthy young men, defined as approximately 400 to 700 ng/dL [15]. The guideline states: "We suggest that testosterone therapy in men with hypogonadism be initiated with any of the testosterone formulations available in the United States, at doses that produce testosterone concentrations in the mid-normal range." [15]. The guideline does not stratify dosing recommendations by ethnicity or pharmacogenomic status.

The 2019 American Urological Association (AUA) guideline on testosterone deficiency similarly recommends titrating to mid-normal testosterone without ethnicity-specific adjustments [16]. Neither guideline acknowledges UGT2B17 polymorphism frequency or SHBG differences by ancestry, creating a gap between population genomics and published clinical recommendations.

Practical Dosing Adjustments for East Asian Patients

Starting Dose

Given slower free-testosterone clearance in likely UGT2B17 deletion carriers and lower average SHBG, a starting dose of 100 mg IM every 2 weeks is more appropriate for East Asian men than the often-cited 200 mg dose [17]. This halving of the initial dose is supported by the 2012 Chinese RCT data showing supratherapeutic peaks at 250 mg every 3 weeks [12] and by first-principles pharmacokinetic reasoning based on lower Vd and slower glucuronidation.

Monitoring Parameters

Clinicians should measure free testosterone (calculated or equilibrium dialysis method) at trough (day 13 to 14 of a 2-week cycle) rather than relying solely on total testosterone [15]. Free testosterone target: 50 to 210 pg/mL per the Endocrine Society reference range for healthy young men [15]. Hematocrit should be checked at baseline, at 3 months, and every 6 months thereafter, with dose reduction or phlebotomy triggered at hematocrit above 54% [15]. Estradiol (sensitive assay, target 20 to 40 pg/mL) warrants monitoring given heightened aromatase activity from CYP19A1 variants [4].

Injection Interval Adjustment

Shortening the injection interval to every 10 days rather than every 14 days at a proportionally lower dose per injection can flatten peak-to-trough swings. For example, 70 mg every 10 days delivers roughly the same weekly dose as 100 mg every 14 days but with a lower Cmax. This strategy may reduce polycythemia risk in East Asian men who are UGT2B17 deletion carriers [18].

Aromatization, Estradiol, and Clinical Consequences

Gynecomastia Risk

East Asian men with high-activity CYP19A1 variants and lower SHBG have a biological substrate for increased estradiol exposure relative to testosterone during TE therapy [5]. A cross-sectional study of 340 Taiwanese men with hypogonadism found gynecomastia present in 31% of those receiving testosterone therapy without aromatase inhibitor co-treatment, compared with 12% in the matched European-ancestry comparison group drawn from a concurrent German cohort (unadjusted comparison, not an RCT) [19]. These data must be interpreted cautiously, but the signal is consistent with the underlying pharmacogenomics.

Bone and Cardiovascular Considerations

Estradiol, not testosterone, is the primary driver of bone mineral density preservation in men [20]. If CYP19A1 high-activity variants increase aromatization, East Asian men may paradoxically receive better bone protection from a given TE dose than would be predicted from testosterone levels alone. Conversely, higher estradiol concentrations may alter cardiovascular risk profiles. The TRAVERSE trial (N=5,246, mean age 57) found no increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men, but the cohort was 80% White and the results may not generalize directly to East Asian men with amplified estradiol responses [21].

Pharmacogenomic Testing: Current State and Clinical Utility

Genotyping for UGT2B17 CNV is not yet part of standard clinical TRT workup in the United States. PharmGKB lists the variant, and several clinical genomic laboratories offer the assay as part of broader pharmacogenomic panels [13]. The cost remains a barrier. A pragmatic alternative is to treat UGT2B17 deletion as the prior-probability default for East Asian patients (given 70 to 80% population frequency) and dose conservatively without waiting for genotyping [2]. Clinicians who do have access to pharmacogenomic testing should note that homozygous deletion carriers (UGT2B17 del/del) will have the most dramatic reduction in testosterone glucuronidation [3].

CYP2C19 and CYP2D6, the enzymes frequently cited in East Asian pharmacogenomics discussions, are not primary routes for testosterone or TE metabolism. Their variant frequencies in East Asian populations are well-documented [22] but are not directly relevant to TE disposition. Citing them in the context of TE is a common error in clinical practice; the relevant enzymes are UGT2B17 and CYP19A1.

Laboratory Reference Ranges and the East Asian Patient

Most U.S. Testosterone reference ranges were established in predominantly European-ancestry cohorts. The widely used 2017 Harmonized Reference Ranges published in the Journal of Clinical Endocrinology and Metabolism (JCEM) set the lower limit of normal at 264 ng/dL and the upper limit at approximately 916 ng/dL for men aged 19 to 39 [23]. These ranges reflect predominantly White and Black participants from NHANES and other U.S. Surveys with limited East Asian representation.

A 2018 study in JCEM of 1,082 community-dwelling Chinese men in Hong Kong found median total testosterone of 15.7 nmol/L (approximately 453 ng/dL), with the 2.5th percentile at 9.1 nmol/L (262 ng/dL), broadly similar to Western ranges [24]. However, SHBG was significantly lower in the Chinese cohort, meaning free testosterone at any given total testosterone was higher. Applying Western total-testosterone thresholds to East Asian men may result in underdiagnosis of men with elevated free testosterone or overdiagnosis of hypogonadism based on artificially lower SHBG-adjusted free-T calculations.

Summary of Dosing Framework for East Asian Men on Testosterone Enanthate

The following framework reflects the pharmacogenomic evidence, the limited ethnicity-stratified trial data, and Endocrine Society monitoring principles:

• Initiate at 100 mg IM every 2 weeks (not 200 mg) in East Asian men without prior pharmacogenomic testing.
• Measure free testosterone at trough (day 13 to 14) targeting 50 to 210 pg/mL.
• Check hematocrit at baseline, 3 months, 6 months. Hold or reduce dose at hematocrit above 54%.
• Measure estradiol (sensitive assay) at 6 to 8 weeks. Target 20 to 40 pg/mL; add anastrozole 0.25 to 0.5 mg twice weekly only if symptomatic and estradiol consistently exceeds 50 pg/mL.
• Consider interval shortening to every 10 days at proportionally reduced per-injection dose to reduce Cmax in men with polycythemia or supraphysiologic peaks.
• Genotype for UGT2B17 CNV if available; homozygous deletion carriers may need dose reduction of an additional 20 to 30%.
• Reassess at 3 months, 6 months, and annually once stable [15].